nabhan et al., 1999; Park et al., 1998), and cyclins a monoclonal antibody specific for parkin protein (see Supplementary Data at http://www.neuron.org/cgi/ accumulate in postmitotic neurons in response to proapoptotic stimuli such as excitotoxicity. We show that content/full/37/5/735/DC1), followed by Western blotting with a polyclonal antibody against hSel-10, indiparkin overexpression suppresses both cyclin E accumulation and apoptosis in postmitotic neurons exposed cated that parkin and hSel-10 are associated ( Figure  1E ). In contrast, immunoprecipitation of an age-matched to kainic acid, an excitotoxin. Furthermore, cyclin E levels are elevated in parkin-deficient primary neurons, inparkin-deficient ARPD frontal cortex extract with a parkin-specific monoclonal antibody failed to copurify hSelcluding midbrain dopamine neurons, and parkin-deficient brain extracts. Of note, cyclin E and additional 10. Parkin antibody immunoprecipitation of normal human frontal cortex extract ( Figure 1E 1D ). Furthermore, a missense mutation in parkin within tination in untransfected HeLa cells may be due to endogenous hSel-10 or a related activity. We therefore the first RING finger (T240R; Figure 1C We sought to confirm the interaction between parkin 10 or a related activity in vivo ( Figure 2B, lanes 3 and 4) . We further investigated whether the E2 ubiquitin-conand hSel-10 in mammalian brain extracts. Immunoprecipitation of normal human frontal cortex extract with jugating enzyme UbcH7 functions in the above parkin . As hSel-10 is known to bind directly to cyclin E, it may recruit cyclin E and other substrates for modificomplex is able to ubiquitinate cyclin E substrate in Figure 4B, lanes 6 and 7) . of endogenous parkin expression (see Figure 5A) tects primary neurons. We sought to extend these studexcitotoxicity. Parkin siRNA treatment alone, in the absence of kainate, failed to alter cyclin E or DAT immunoies to primary dopamine neuron cultures. Embryonic day 13.5 (E13.5) primary culture midbrain dopamine neureactivity ( Figure 7U-7X) , and thus parkin "knockdown" is not directly toxic but appears to sensitize neurons to rons, identified by immunohistochemical staining for the dopamine transporter (DAT) (Nirenberg et al., 1996) , kainate excitotoxicity. Parkin siRNA treatment failed to alter dopamine neuwere transfected with parkin siRNA (Figures 7F-7J and 7P-7T) or control siRNA ( Figures 7A-7E and 7K-7O) and ron sensitivity to 1-methyl-4-phenylpyridinium (MPP ϩ ; 10 M) at a toxin dose that (in control siRNA-treated subsequently exposed to kainate, as above. As predicted, parkin "knockdown" dopamine neurons displayed incultures) led to a reduction in DAT immunoreactivity comparable to the kainate treatment ( Figure 7X) . We creased accumulation of cyclin E ( Figure 7S ) and increased apoptosis (Figures 7J and 7T) Although the molecular mechanism of this protection SCF complexes are modular: for instance, Skp1 can remains unclear, it appears to differ from that underlying interact with several F-box adaptor proteins, thereby the protection of primary neurons from excitotoxingenerating functional diversity. It is of interest to determediated apoptotic death described in our report. mine whether parkin associates with adaptor proteins Finally, we note that the protective role of parkin overother than hSel-10 (although we failed to detect an interexpression suggests a potential treatment approach for action with other F-box/WD repeat proteins in this PD and other diseases that relate to glutamate excitostudy), as such complexes would likely display different toxicity. Thus, further understanding of the parkin ubisubstrate specificities. This may explain the diverse tarquitin ligase complex and its mechanism of action may gets that have been reported for parkin, including lead to novel diagnostic and therapeutic tools. 
